CosIng Checker
CosIng Checker
EU cosmetic ingredients, restrictions and safety
Login
RestrictedBinding ruleGBOriginal is EnglishOfficial-source import checked

Quinine

The consolidated GB Cosmetics Regulation lists this record in Annex III.

All Great Britain recordsOpen ingredient profileCompare all marketsOpen official source

Regulatory decision and full conditions

Status
Restricted
Legal role
Binding rule
Regulatory summary
The consolidated GB Cosmetics Regulation lists this record in Annex III.
Conditions and restrictions
(a) Hair rinse-off products · (a) 0,5% (as quinine base)

Substance identity

Official source name
Quinine
CAS
130-95-0
EC
205-003-2
Identity mapping
cas_number
Linked ingredient
QUININE
Search this identity across the siteCAS 130-95-0EC 205-003-2

Linked CosIng identity data

Names and aliases

QUININEquininechininum

CosIng description: Cinchonan-9-ol, 6'-methoxy-, (8.alpha., 9R)-

EU inventory restriction note: III/21

Recorded cosmetic function: DENATURANT, FRAGRANCE, HAIR CONDITIONING

Function pages:DENATURANT, FRAGRANCE, HAIR CONDITIONING

View the complete ingredient profile

Cross-market snapshot for this identity

Exact linked records currently present in this site. An absent market means no imported exact match, not permission to use the substance.

8 market datasets
PubChem 2D chemical structure for CAS 130-95-0
CAS 130-95-0PubChem CID 3034034

Verified chemistry for CAS 130-95-0

Quinine

Quinine is a cinchona alkaloid that is cinchonidine in which the hydrogen at the 6-position of the quinoline ring is substituted by methoxy. It has a role as a non-narcotic analgesic, an antimalarial and a muscle relaxant. It is a conjugate base of a quinine(1+). It derives from a hydride of an (8S)-cinchonan. — ChEBI

IUPAC name
(R)-[(2S,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol
Molecular formula
C20H24N2O2
Molecular weight
324.4 g/mol
Exact mass
324.183778013 Da
Monoisotopic mass
324.183778013 Da
XLogP3
2.9
Topological polar surface area
45.6 Ų
Molecular complexity
457.0
Formal charge
0
Hydrogen-bond donors
1
Hydrogen-bond acceptors
4
Rotatable bonds
4
Heavy atoms
24
Covalent units
1

Names and synonyms reported to PubChem

ChinineChinin(-)-Quinine(8S,9R)-Quinine6'-Methoxycinchonidine(R)-(-)-quinine6-Methoxycinchoninechininum
16 more reported names
quininaRezquinChininum purum(8S,9R)-6'-Methoxycinchonan-9-ol(R)-(-)-Quinine, 6-methoxycinchonidineA7V27PHC7ACHEBI:15854(8-alpha,9R)-6'-Methoxycinchonan-9-olNSC-192949(R)-(6-methoxyquinolin-4-yl)((2S,4S,8R)-8-vinylquinuclidin-2-yl)methanol2-Quinuclidinemethanol, alpha-(6-methoxy-4-quinolyl)-5-vinyl-(R)-[(1S,2S,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl](6-methoxyquinolin-4-yl)methanolQuinsonQuinsul(R)-((1S,2S,4S,5R)-5-ethenyl-1-azabicyclo(2.2.2)octan-2-yl)(6-methoxyquinolin-4-yl)methanol(R)-((2S,4S,5R)-5-ethenyl-1-azabicyclo(2.2.2)octan-2-yl)-(6-methoxyquinolin-4-yl)methanol
Open full PubChem recordSafety and hazards at PubChemPubChem annotationsChemical classifications3D structure image
External database identifiers
Advanced structure statistics
Defined atom stereocentres
4
Undefined atom stereocentres
0
Defined bond stereocentres
0
Undefined bond stereocentres
0
3D pharmacophore features
9
3D rings
3
3D hydrophobes
1
3D acceptor features
3
3D donor features
1
3D anionic centres
0
3D cationic centres
1
3D conformers
7
Effective 3D rotors
5.2
Machine-readable structure identifiers
SMILES
COC1=CC2=C(C=CN=C2C=C1)[C@H]([C@@H]3C[C@@H]4CCN3C[C@@H]4C=C)O
InChI
InChI=1S/C20H24N2O2/c1-3-13-12-22-9-7-14(13)10-19(22)20(23)16-6-8-21-18-5-4-15(24-2)11-17(16)18/h3-6,8,11,13-14,19-20,23H,1,7,9-10,12H2,2H3/t13-,14-,19-,20+/m0/s1
InChIKey
LOUPRKONTZGTKE-WZBLMQSHSA-N

Evidence from additional scientific databases

NIH PubChem PUG-View
Exact identifier match3034034

Attributed physical-property, hazard, environmental and use annotations.

  • Signal: Danger Source: European Chemicals Agency (ECHA)
  • GHS Hazard Statements: H302 (22.9%): Harmful if swallowed [Warning Acute toxicity, oral]; H315 (28.4%): Causes skin irritation [Warning Skin corrosion/irritation]; H317 (99.5%): May cause an allergic skin reaction [Warning Sensitization, Skin]; H319 (28.4%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]; H334 (83.1%): May cause allergy or asthma symptoms or breathing difficulties if inhaled [Danger Sensitization, respiratory] Source: European Chemicals Agency (ECHA)
  • Precautionary Statement Codes: P233, P260, P261, P264, P264+P265, P270, P271, P272, P280, P284, P301+P317, P302+P352, P304+P340, P305+P351+P338, P321, P330, P332+P317, P333+P317, P337+P317, P342+P316, P362+P364, P403, and P501 (click each P-code to see the statement) Source: European Chemicals Agency (ECHA)
  • ECHA C&L Notifications Summary: Aggregated GHS information provided per 201 reports by companies from 10 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.; Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website. Source: European Chemicals Agency (ECHA)
  • Signal: Warning Source: Hazardous Chemical Information System (HCIS), Safe Work Australia
  • GHS Hazard Statements: H302: Harmful if swallowed [Warning Acute toxicity, oral]; H317: May cause an allergic skin reaction [Warning Sensitization, Skin] Source: Hazardous Chemical Information System (HCIS), Safe Work Australia
  • Precautionary Statement Codes: P261, P264, P270, P272, P280, P301+P317, P302+P352, P321, P330, P333+P317, P362+P364, and P501 (click each P-code to see the statement) Source: Hazardous Chemical Information System (HCIS), Safe Work Australia
  • Signal: Danger Source: Hazardous Substances Data Bank (HSDB)
  • GHS Hazard Statements: H315: Causes skin irritation [Warning Skin corrosion/irritation]; H317: May cause an allergic skin reaction [Warning Sensitization, Skin]; H319: Causes serious eye irritation [Warning Serious eye damage/eye irritation]; H334: May cause allergy or asthma symptoms or breathing difficulties if inhaled [Danger Sensitization, respiratory] Source: Hazardous Substances Data Bank (HSDB)
  • Precautionary Statement Codes: P233, P260, P261, P264, P264+P265, P271, P272, P280, P284, P302+P352, P304+P340, P305+P351+P338, P321, P332+P317, P333+P317, P337+P317, P342+P316, P362+P364, P403, and P501 (click each P-code to see the statement) Source: Hazardous Substances Data Bank (HSDB)
  • Health Effects: It is usual for quinine in therapeutic doses to cause cinchonism; in rare cases, it may even cause death (usually by pulmonary edema). Quinine can worsen hemoglobinuria, myasthenia gravis and optic neuritis. It can cause paralysis if accidentally injected into a nerve, and is extremely toxic in overdose[Wikipedia] Source: Toxin and Toxin Target Database (T3DB)
  • Toxicity Summary: IDENTIFICATION AND USE: Quinine is a bulky, white, amorphous powder or crystalline alkaloid, used as medication: non-narcotic analgesics; antimalarial; central muscle relaxants. It is also used as flavor in carbonated beverages. HUMAN EXPOSURE AND TOXICITY: Serious hypersensitivity reactions, including anaphylactic shock, anaphylactoid reactions, urticaria, serious skin rashes, angioedema, facial edema, bronchospasm, and pruritus, have been reported with quinine. In addition, thrombocytopenia, hemolytic uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP), immune thrombocytopenic purpura, blackwater fever, disseminated intravascular coagulation, leukopenia, neutropenia, granulomatous hepatitis, and acute interstitial nephritis have been reported and may also be due to hypersensitivity reactions to the drug. Potentially fatal cardiac arrhythmias, including torsades de pointes and ventricular fibrillation, have been reported rarely during quinine therapy. At least 1 case of fatal ventricular arrhythmia has been reported in a geriatric patient with preexisting prolonged QT interval treated with IV quinine sulfate for Plasmodium falciparum malaria. Visual impairment can range Source: Hazardous Substances Data Bank (HSDB)
  • Toxicity Summary: The theorized mechanism of action for quinine and related anti-malarial drugs is that these drugs are toxic to the malaria parasite. Specifically, the drugs interfere with the parasite's ability to break down and digest hemoglobin. Consequently, the parasite starves and/or builds up toxic levels of partially degraded hemoglobin in itself. Source: Toxin and Toxin Target Database (T3DB)

Mapped by: Existing checksum-valid CAS to unique PubChem CID match. Retrieved: 2026-08-31. Open source record

Scientific classifications and hazard annotations provide context and do not replace the market-specific regulatory decision shown above.

Additional source coverage and match status
SourceResultChecked
NIH PubChem PUG-ViewExact match2026-08-31

A recorded no-match is useful evidence that the source was checked; it is not a claim that the substance does not exist elsewhere.

Retrieved from NIH PubChem on 2026-08-31 by checksum-valid CAS matching. Chemical properties do not replace the regulatory decision on this page.

Official source and provenance

Registered source
Great Britain Cosmetics Regulation — consolidated Annexes II–VI and amendments
Source reference
GB Cosmetics Regulation, Annex III, entry 21
Source record ID
III-21
Source version
2026-08-15
Source language
English
Translation status
Original is English
Effective date
2026-08-15
Source updated
2026-08-19
Snapshot checked
2026-08-30 04:51 UTC
Validation method
legislation.gov.uk XML table parse; {'II': 1758, 'III': 326, 'IV': 154, 'V': 57, 'VI': 34}
SHA-256
e3a386d950f54c6e7a7f9e784d1bd46e52de725137e89d5630709824475215d8

Registered dataset notes

Dataset coverage
Complete consolidated GB Annexes II–VI, with later amendments versioned separately
Authority note
Binding GB schedules and versioned amendments to retained Regulation 1223/2009; applies to England, Wales and Scotland, not Northern Ireland
Source licence
Open Government Licence v3.0 / Crown copyright
Attribution
Contains public sector information licensed under the Open Government Licence v3.0.
Inspect the exact official sourceRegulator guidance

How this record fits the market dataset

2329
current Great Britain records
326
records marked Restricted
2329
records from this source version
2015
market records with CAS identity

Status distribution

Permitted list with conditions: 245Prohibited: 1758Restricted: 326

Condition text is present on 517 of 2329 current records. An empty condition field is interpreted according to the record type above; it is never converted into an unrestricted-use claim.

Great Britain market context

Complete consolidated annex dataset

Coverage version: GB retained Regulation 1223/2009 schedules, effective 15 August 2026

Current consolidated Annexes II–VI for England, Scotland and Wales.

Verification checklist

  1. Confirm INCI/CAS/EC identity.
  2. Review every current GB Annex II–VI match.
  3. Check commencement dates and later statutory instruments.
  4. Verify SCPN, responsible-person, safety-report and labelling duties.

Official market sources

Verification workflow and record completeness

Before using this result in a compliance decision

  1. Confirm that “Quinine” and every CAS/EC identifier refer to the material in your supplier specification.
  2. Confirm INCI/CAS/EC identity.
  3. Review every current GB Annex II–VI match.
  4. Check commencement dates and later statutory instruments.
  5. Verify SCPN, responsible-person, safety-report and labelling duties.
  6. Document the source version and recheck the regulator before manufacture, notification or market placement.

Fields available in this record

  • Official substance nameAvailable
  • CASAvailable
  • ECAvailable
  • Separate condition textAvailable
  • Effective dateAvailable
  • Snapshot hash and methodAvailable

Questions this page answers

This substance is not unrestricted: cosmetic use is subject to the conditions in the cited official record. Check product type, body area, concentration, purity and warning requirements before deciding whether a formulation is compliant.

If this row does not reproduce conditions, open the cited official detail because omission does not mean unrestricted use. No annex match is not approval and does not cover Northern Ireland, which follows the applicable EU framework.

The record cites GB Cosmetics Regulation, Annex III, entry 21, source version 2026-08-15. Open the official source.

No. CAS helps resolve identity, but jurisdictions can classify the same substance differently and can apply different product scopes, limits, warnings and transition dates.

Stable citation

Quinine. GB Cosmetics Regulation, Annex III, entry 21. Great Britain. Source version 2026-08-15. CosIng Checker regulatory record: https://cosingchecker.com/regulations/gb/records/6141/

Cite the regulator as the legal authority. This page is a structured evidence index and verification aid, not a substitute for the official text or professional legal assessment.

Interpretation and limits for Great Britain

This substance is not unrestricted: cosmetic use is subject to the conditions in the cited official record.

Check product type, body area, concentration, purity and warning requirements before deciding whether a formulation is compliant.

How to interpret the legal role

The cited row forms part of a binding rule or legally incorporated list for this market.

Evidence on this page

  • Recorded outcome: Restricted
  • Legal role: Binding rule
  • Source version: 2026-08-15
  • Effective date: 2026-08-15

What it does not prove

No annex match is not approval and does not cover Northern Ireland, which follows the applicable EU framework.

Further authoritative substance research

These sources can add identity, safety, exposure or hazard context. A link is not evidence that the database contains this exact substance, and none of these sources overrides the market decision above.

Cosmetic Ingredient Review safety assessments

Expert Panel conclusions, assessed ingredient groups, use conditions, dates and report documents

Independent expert review considered by FDA; not a government approval or binding market rule

Research this identity at the source

FDA Global Substance Registration System

UNII identifiers, preferred names, substance types, codes and public substance relationships

Identity registry only; UNII availability does not imply FDA review or approval

Research this identity at the source

ILO/WHO International Chemical Safety Cards

Hazards, symptoms, first aid, storage, incompatibilities and physical properties for covered chemicals

International occupational chemical-safety reference; not cosmetic-use approval

Research this identity at the source

Japan NITE-CHRIP

Chemical identity, Japanese and foreign legal lists, GHS hazards and exposure-related information

Chemical-management evidence; cosmetic status remains governed by the applicable MHLW standard and market rules

Research this identity at the source

NIOSH Pocket Guide to Chemical Hazards

REL, PEL, IDLH, properties, exposure routes, symptoms, target organs, first aid and measurement methods for covered workplace chemicals

US occupational-health guidance and limits; not a cosmetic ingredient decision

Research this identity at the source

OECD eChemPortal

Gateway to authority-owned physical-property, fate, ecotoxicity, toxicity, exposure and GHS records

Discovery gateway; each linked authority remains responsible for its data

Research this identity at the source

US EPA CompTox CTX APIs

API key required for import

DTXSID identity, experimental and predicted properties, toxicity, bioactivity, exposure and environmental data

Scientific and computational evidence; predictions must remain labelled and do not determine cosmetic legality

Research this identity at the source